Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS)
This study, called Lunsayil LTE, is an important research project for people with a skin condition called Hidradenitis Suppurativa (HS). HS causes painful lumps and boils, and can be very challenging. This study is testing a new medicine called spesolimab to see if it can help. It's an ‘extension’ study, which means it builds on earlier research. Researchers are particularly interested in understanding the long-term effects of spesolimab, especially focusing on any side effects that might come up while people are taking the medicine. They want to know if it's safe and how well it helps over a longer period. Both men and women aged 18 and over can potentially take part.
At a glance
What is this study about?
Imagine a special research project looking at a new way to treat a skin condition called Hidradenitis Suppurativa, or HS. HS causes painful, pus-filled lumps under the skin, often in areas where skin rubs together, like armpits or groin. It can be a very uncomfortable condition and difficult to manage.
This particular study is called Lunsayil LTE, and it's trying to understand more about a medicine called spesolimab. Think of it as a deeper dive into how this medicine works over a longer time. Researchers want to see if spesolimab can help reduce the symptoms of HS and improve people's quality of life. An important part of this research is carefully watching for any side effects people might experience while taking the medicine.
This study is an 'extension' study. This often means that some participants might have already been part of an earlier study looking at spesolimab. Now, the researchers want to continue to follow these patients, and possibly new ones, for a longer period to get a more complete picture of spesolimab's safety and how well it works when used for an extended time. This helps doctors and scientists understand if it could be a good long-term treatment option for HS.
Key takeaways
- This study is testing a new medicine, spesolimab, for Hidradenitis Suppurativa (HS).
- It's an 'extension' study, focusing on the long-term safety and effects of the treatment.
- Participants must be 18 years or older, both men and women are included.
- You might receive the active medicine or a placebo.
- Close monitoring for side effects is a key part of the study.
- Participation is voluntary, and you can withdraw at any time.
Who may be eligible?
To be considered for this study, you need to be at least 18 years old. There's no upper age limit, meaning older adults can also take part if they meet other requirements.
Both men and women are welcome to participate in this study. The researchers want to understand how the treatment works for everyone, regardless of gender.
Because this is an 'extension' study for Hidradenitis Suppurativa, it's likely that participants will have a confirmed diagnosis of HS. There might be other specific health requirements or conditions that would make someone suitable or unsuitable, which a doctor involved in the study would discuss with you in detail.
- Are you 18 years old or older?
- Do you have a diagnosis of Hidradenitis Suppurativa (HS)?
- Are you able to attend regular study appointments?
- Are you comfortable with the possibility of receiving a placebo?
- Are you willing to have your health closely monitored?
This is a guide only — the research team will confirm whether you can take part.
What does participation involve?
If you decide to take part in this study, you might receive either the study medicine, spesolimab, or a placebo. A placebo looks just like the real medicine but contains no active drug. This helps researchers understand if the medicine itself is causing any changes. You won't know if you're getting the active medicine or the placebo, and neither will your study doctor, until the study is over.
Taking part will involve regular visits to the study clinic. During these visits, the study team will carry out various checks and assessments. This might include physical exams, blood tests, and questions about your health and how you're feeling. They will also keep a close eye on your HS symptoms and any side effects you might experience.
The total length of time you'd be involved in the study can vary, but because it’s an 'extension' study focused on long-term effects, it will likely involve a commitment over several months, or potentially even longer. There will also be follow-up appointments after you've finished taking the study medicine to ensure your health is alright.
Potential risks and benefits
Locations (14)
- —Spain
- —Slovakia
- —France
- —Finland
- —Bulgaria
- —Poland
- —Belgium
- —Czechia
- —Greece
- —Denmark
- —Italy
- —Lithuania
+2 more sites — see the official record for the full list.
Common questions
What is Hidradenitis Suppurativa (HS)?
HS is a long-term skin condition that causes painful lumps, boils, and abscesses, often in areas where skin rubs together.
What is spesolimab?
Spesolimab is an investigational medicine being tested to see if it can help treat HS symptoms.
What is an 'extension' trial?
An extension trial means it follows earlier research, looking to understand how the medicine works over a longer period, especially regarding safety.
Will I definitely get the active medicine?
No, you might receive the active medicine or a 'placebo' (a dummy medicine) to help researchers understand if the drug is truly effective.
What does 'treatment emergent adverse events' mean?
This refers to any health problems or side effects that happen to a patient while they are part of the study and taking the medicine.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.